Cardiovascular Drug Discovery: A Perspective from a Research-Based Pharmaceutical Company

Pharmaceutical Company Sponsorship of Research: A Review

Many studies have shown that pharmaceutical companies' funding of clinical trials is associated with pro-industry results. This article reviews the literature on that association, confirming its existence, and discusses its causes and potential responses. The mechanisms of industry influence are varied, more than is usually acknowledged. It is straightforward to identify a number of distinct ki...

Translational medicine for stroke drug discovery: the pharmaceutical industry perspective.

Over the past 20 years, an estimated $1 billion has been spent in research and development of stroke therapeutics; however, this huge investment has failed to produce a clinically efficacious drug with the exception of the thrombolytic agent Activase (tPA). This sobering reality has been the subject of numerous reflections by renowned leaders in stroke research with special focus on the most re...

A New Pharmaceutical Commons: Transforming Drug Discovery

Drug discovery: a historical perspective.

Driven by chemistry but increasingly guided by pharmacology and the clinical sciences, drug research has contributed more to the progress of medicine during the past century than any other scientific factor. The advent of molecular biology and, in particular, of genomic sciences is having a deep impact on drug discovery. Recombinant proteins and monoclonal antibodies have greatly enriched our t...

From Food to Drug: Avicenna’s Perspective, a Brief Review

The Food and drug were developed by pharmacists and physicians, in particular Persian scientists throughout medical history. There was an especial view on the subject of nutrition and medications in Persian medicine (PM). Avicenna was one of the main Persian physicians who contributed to this field in the Canon of medicine “Al-qanun-fi-al-tibb”, his main medical and pharmaceutical text book in ...